Home/Filings/4/0001209191-23-016977
4//SEC Filing

Garland Jonathan Todd 4

Accession 0001209191-23-016977

CIK 0001831915other

Filed

Mar 6, 7:00 PM ET

Accepted

Mar 7, 7:45 PM ET

Size

8.4 KB

Accession

0001209191-23-016977

Insider Transaction Report

Form 4
Period: 2023-03-03
Garland Jonathan Todd
Chief Commercial Officer
Transactions
  • Award

    Employee Stock Option (right to buy)

    2023-03-03+66,77366,773 total
    Exercise: $10.61Exp: 2033-03-03Common Stock (66,773 underlying)
  • Award

    Restricted Stock Units

    2023-03-03+44,18044,180 total
    Common Stock (44,180 underlying)
Footnotes (3)
  • [F1]1/48th of the shares subject to the option shall vest monthly over four years from the vesting commencement date of March 3, 2023. The option becomes fully vested on March 3, 2027.
  • [F2]Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
  • [F3]The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested.

Issuer

Cytek Biosciences, Inc.

CIK 0001831915

Entity typeother

Related Parties

1
  • filerCIK 0001924824

Filing Metadata

Form type
4
Filed
Mar 6, 7:00 PM ET
Accepted
Mar 7, 7:45 PM ET
Size
8.4 KB